Universal Biosensors, Inc.

Equities

UBI

AU000000UBI2

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 01:11:25 2024-04-23 am EDT 5-day change 1st Jan Change
0.17 AUD +3.03% Intraday chart for Universal Biosensors, Inc. -5.56% -15.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Universal Biosensors Opens AU$10 Million Rights Issue MT
Universal Biosensors to Raise AU$10 Million for Technology Development MT
H&G High Conviction Reports Flat Performance for March Quarter MT
Transcript : Universal Biosensors, Inc. - Shareholder/Analyst Call
Australian Shares Rise as Central Bank Maintains Interest Rates MT
Universal Biosensors Secures US FDA Approval for Coagulation Analyzer Device; Shares Surge 78% MT
Transcript : Universal Biosensors, Inc., 2023 Earnings Call, Mar 07, 2024
Universal Biosensors Narrows 2023 Loss on Absence of Impairment, Higher Revenue; Shares Down 6% MT
Universal Biosensors, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Universal Biosensors Grows H2 2023 Sales by 55% MT
Transcript : Universal Biosensors, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Universal Biosensors, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Universal Biosensors' Coagulation Analysis Device Gets Approval in Europe MT
Universal Biosensors Secures Marketing Approval, First Order for Coagulation Analyzer Device in India MT
Universal Biosensors Secures First Major Tender to Supply Xprecia Prime in Italy MT
Transcript : Universal Biosensors, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Australian Shares Flat Ahead of Central Bank Policy Meeting MT
Universal Biosensors Narrows Net Loss 74% in H1 MT
Universal Biosensors, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Universal Biosensors, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Universal Biosensors, Inc. - Shareholder/Analyst Call
Universal Biosensors Trims Q1 Loss on Lower Expenses, Absence of Intangible Assets Impairment MT
Universal Biosensors, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Universal Biosensors Launches Blood Glucose Monitoring Product for Dogs and Cats MT
Universal Biosensors Introduces Sixth Product on Sentia Wine Testing Platform MT
Chart Universal Biosensors, Inc.
More charts
Universal Biosensors, Inc. is a biosensor company. The Company is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. UBI Stock
  4. News Universal Biosensors, Inc.
  5. Universal Biosensors : Up 5% After Canadian Unit Secures Deal With Bayer